Singapore, June 20 -- CanSino Biologics Inc. has developed and launched its 13-valent pneumococcal conjugate vaccine, trade name "iPneucia", optimised for China's local pneumococcal epidemiology, aiming to provide more precise and safer protection for Chinese children.

The main advantage of iPneucia is its deep optimization based on China's local epidemiological characteristics. Streptococcus pneumoniae is categorised into different serotypes based on polysaccharide structure and biochemical traits. However, not all serotypes pose the same threat; their pathogenicity and disease burden vary.

Research indicates that serotypes 19F, 19A, 7F, and 3 are the four most burdensome for Chinese children, accounting for over 60% of cases. These se...